Our technology platform is protected by a total of 19 multinational patents. The state of art relies on over expressing various cytokine genes by transforming a critical regulatory factor into specific human cell lines. In addition, a second cellular factor was introduced into these cell lines to prolong the life span of cells up to several months instead of only few weeks. Application of these core technologies along with the bioengineering and protein purification techniques ensure large quantity production of high purity of the bio-active cytokines. The advantages of natural form of human cytokines over bacterial recombinant proteins are the higher stability and superb efficacy when subjected into circulation of human body. Our overall technology platform has become the main stream of protein drug development in pharmaceutical industry for years to come.